Evidence map›Paper›PMID 33217961›Full record

ArticleBiomedicines2020

Anti-MAP Triple Therapy Supports Immunomodulatory Therapeutic Response in Crohn's Disease through Downregulation of NF-κB Activation in the Absence of MAP Detection.

Ahmad Qasem, Erij Elkamel, Saleh A Naser

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Sarcoidosis,Microorganisms · 2023
    Review
  4. The evidence forTranslational cancer research · 2023
    Review
  5. Review
  6. Bovine Immunity and Vitamin DMicroorganisms · 2022
    Review
  7. Review
  8. Quantitative Risk Assessment of Exposure toFoods (Basel, Switzerland) · 2022
    Article
  9. Frontiers in cellular and infection microbiology · 2022
    Article
  10. Article
  11. Modulation ofInternational journal of molecular sciences · 2021
    Article
  12. Article
  13. Observational
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ahmad QasemDivision of Molecular Microbiology, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, 4110 Libra Drive, Orlando, FL 32816, USA.
Erij ElkamelDivision of Molecular Microbiology, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, 4110 Libra Drive, Orlando, FL 32816, USA.ORCID 0000-0002-6691-9402
Saleh A NaserDivision of Molecular Microbiology, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, 4110 Libra Drive, Orlando, FL 32816, USA.ORCID 0000-0001-9222-4527
University of Central Florida · US

Funding

Florida Legislative grant 2015-2020
6 · The paper itself

Abstract

We previously reported that the triple antibiotic formulation, known as anti-MAP therapy, exhibits unique synergistic antimicrobial activity and should be effective for treatment of Crohn's disease (CD) associated with

Indexed as

anti-MAP therapyCrohn’s diseasecytokinesIBDinflammationMAPmycobacterium paratuberculosis

Identifiers

PMID33217961
PMCPMC7698721
OpenAlexW3104220983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.